Literature DB >> 6486312

Squamous carcinoma of the floor of the mouth.

A R Shaha, R H Spiro, J P Shah, E W Strong.   

Abstract

We reviewed our experience with 320 patients treated for squamous cell carcinoma of the floor of the mouth from 1964 through 1977. The patients were evenly distributed according to clinical stage. Treatment consisted of surgery (77 percent of patients), surgery and adjunctive radiation therapy (19 percent of patients), or radiation therapy only (4 percent of patients). Most of the patients with favorable (T1) primary tumors had a simple peroral excision (78 percent) with marginal mandibulectomy when indicated (22 percent). Marginal mandibulectomy was still possible in many patients with T2 or T3 lesions (56 percent). Synchronous or metachronous second primary cancers were documented in 33 percent of the patients, most of which occurred in the head and neck region. Seventeen percent of the patients who had elective neck dissection had microscopic metastasis. More than a third of the patients with clinically positive nodes had negative neck specimens histologically. In patients with histologically positive nodes, 60 percent had involvement at multiple levels. The 5 year determinate cure for the entire group was 65 percent. According to stage, 88, 80, 66 and 32 percent of patients with stages I, II, III, and IV disease, respectively, were alive and well 5 years after treatment. This seems to be a significant improvement when compared with the last report from our hospital.

Entities:  

Mesh:

Year:  1984        PMID: 6486312     DOI: 10.1016/0002-9610(84)90369-6

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

1.  Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients.

Authors:  Waseem Jerjes; Tahwinder Upile; Aviva Petrie; Andrew Riskalla; Zaid Hamdoon; Michael Vourvachis; Kostas Karavidas; Amrita Jay; Ann Sandison; Gareth J Thomas; Nicholas Kalavrezos; Colin Hopper
Journal:  Head Neck Oncol       Date:  2010-04-20

2.  Radiomics analysis of [18F]-fluoro-2-deoxyglucose positron emission tomography for the prediction of cervical lymph node metastasis in tongue squamous cell carcinoma.

Authors:  Takaharu Kudoh; Akihiro Haga; Keiko Kudoh; Akira Takahashi; Motoharu Sasaki; Yasusei Kudo; Hitoshi Ikushima; Youji Miyamoto
Journal:  Oral Radiol       Date:  2022-03-07       Impact factor: 1.852

3.  Breast metastases from a floor of the mouth carcinoma.

Authors:  José Luis López Guerra; Palmira Foro Arnalot; Manuel Algara López
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

Review 4.  [Surgical treatment options for squamous cell carcinoma of the oral cavity].

Authors:  Michael Rasse
Journal:  Wien Med Wochenschr       Date:  2008

Review 5.  Management of oral cancer.

Authors:  A E Brown; J D Langdon
Journal:  Ann R Coll Surg Engl       Date:  1995-11       Impact factor: 1.891

6.  Mandibular invasion of squamous cell carcinoma: factors determining surgical resection of mandible using computerized tomography and histopathologic study.

Authors:  L Deepanandan; Vinod Narayanan; M F Baig
Journal:  J Maxillofac Oral Surg       Date:  2010-06-04

7.  Analyzing the factors that influence occult metastasis in oral tongue cancer.

Authors:  Jung-Hyun Shin; Hye-Jung Yoon; Soung-Min Kim; Jong-Ho Lee; Hoon Myoung
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2020-04-30

8.  Overall and disease-specific survival outcomes following primary surgery for oral squamous cell carcinoma: analysis of consecutive 67 patients.

Authors:  Yookyeong Carolyn Sim; Jong-Hyun Hwang; Kang-Min Ahn
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2019-04-29

9.  Cyclin D1 expression and cervical metastases in squamous cell carcinoma of the mouth.

Authors:  Gerson Schulz Maahs; Denise Cantarelli Machado; Emilio Antonio Jeckel-Neto; Vinicius Schenk Michaelses
Journal:  Braz J Otorhinolaryngol       Date:  2007 Jan-Feb
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.